Liposomal Formulations in Clinical Use: An Updated Review

Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape

(2016) Claudia Zylberberg et al.   DRUG DELIVERY

To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?

(2016) F. Danhier   JOURNAL OF CONTROLLED RELEASE

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

(2015) Edouard Alphandéry et al.   Expert Review of Anticancer Therapy

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

(2015) Andreas Wicki et al.   JOURNAL OF CONTROLLED RELEASE

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

(2015) Jonathan E. Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01

(2014) Ana Tari Ashizawa et al.   Expert Opinion on Drug Delivery

Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor

(2014) Jun Chen et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,®/Doxil®—A Cerebral Open Flow Microperfusion Pilot Study

(2014) Thomas Birngruber et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery

(2014) Vladimir P. Torchilin   NATURE REVIEWS DRUG DISCOVERY

Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

(2014) Pieter J. Gaillard et al.   PLoS One

A review of the current status of siRNA nanomedicines in the treatment of cancer

(2013) Pauline Resnier et al.   BIOMATERIALS

Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2013) Meir Wetzler et al.   Clinical Lymphoma Myeloma & Leukemia

Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer

(2013) Marije Slingerland et al.   CLINICAL THERAPEUTICS

Stimuli-responsive nanocarriers for drug delivery

(2013) Simona Mura et al.   NATURE MATERIALS

Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection

(2013) J P Clancy et al.   THORAX

Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures

(2013) JIANLIN LI et al.   Experimental and Therapeutic Medicine

Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy

(2013) Jong-Min Lee et al.   Biomed Research International

Victories and deceptions in tumor immunology

(2013) Guido Kroemer et al.   OncoImmunology

Phototriggerable Liposomes: Current Research and Future Perspectives

(2013) Anu Puri   Pharmaceutics

Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research

(2012) Susana Patricia Egusquiaguirre et al.   Clinical & Translational Oncology

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies

(2011) Nicholas P. Farrell   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Liposomal drug formulations in cancer therapy: 15 years along the road

(2011) Marije Slingerland et al.   DRUG DISCOVERY TODAY

High-Dose Bupivacaine Remotely Loaded into Multivesicular Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma Concentrations After Subcutaneous Administration in Humans

(2010) Elyad M. Davidson et al.   ANESTHESIA AND ANALGESIA

Advances in Platinum Chemotherapeutics

(2010) Benjamin W. Harper et al.   CHEMISTRY-A EUROPEAN JOURNAL

Amphotericin B Lipid Complex (Abelcet®) in the treatment of invasive mycoses: the North American experience

(2010) J. Lister   EUROPEAN JOURNAL OF HAEMATOLOGY

Strategies for Cancer Vaccine Development

(2010) Matteo Vergati et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Immunotherapy for Lung Cancer

(2010) Penelope A. Bradbury et al.   Journal of Thoracic Oncology

Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)

(2009) R.C.F. Leonard et al.   BREAST

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma

(2009) M. A. Rodriguez et al.   CANCER

Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin

(2009) Teni Boulikas   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer

(2009) Martin E. Eichhorn et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

(2009) N. Mylonakis et al.   LUNG CANCER

T4 endonuclease V: review and application to dermatology

(2008) Jennifer A Cafardi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Characterization of Nebulized Liposomal Amikacin (Arikace™) as a Function of Droplet Size

(2008) Zhili Li et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY